# Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

> **NCT03241940** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 33 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- CD19 Positive
- Minimal Residual Disease
- Philadelphia Chromosome Positive
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Chimeric Antigen Receptor T-Cell Therapy
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03241940
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-20
- **Primary completion:** 2025-04-03
- **Final completion:** 2035-08-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241940, "Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03241940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*